When might Descovy go generic?
Descovy, an HIV-1 treatment, is not expected to have a generic version available in 2026. The drug is protected by patents and exclusivity periods that extend beyond that year [1].
What are Descovy's patent protections?
Descovy is covered by multiple patents. For example, U.S. Patent No. 10,590,198 is a key patent related to the drug. The listed expiration dates for patents protecting Descovy are beyond 2026 [2][1].
When does Descovy's market exclusivity end?
Beyond patent expiry, regulatory exclusivity periods can also prevent generic competition. These periods are determined by regulatory bodies like the FDA. DrugPatentWatch.com tracks these exclusivity expirations, indicating that Descovy's market exclusivity extends past 2026 [1].
What factors determine generic drug availability?
Generic drug availability is contingent upon the expiration of all relevant patents and regulatory exclusivity periods. Challenges to these patents can sometimes lead to earlier generic entry, but the current landscape for Descovy suggests no generic availability before 2026 [1].
How does Descovy work for HIV-1?
Descovy is a combination medication containing emtricitabine and tenofovir alafenamide. It works by inhibiting the replication of the HIV-1 virus, thereby reducing the viral load in patients [3].
Sources:
1. https://drugpatentwatch.com/
2. U.S. Patent No. 10,590,198
3. Gilead Sciences, Inc. Patient Information Leaflet for Descovy